Institutional Review Board, Hospital for Special Surgery
August 01, 2016
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Jennifer Solomon, MD
Richard Herzog, MD
Jonathan Kirschner, MD
Christopher Lutz, MD
This is a multicenter prospective cohort study on intradiscal platelet rich plasma injections as treatment for discogenic low back pain. All participants will receive the study treatment. 10-12 study participants will be enrolled at Hospital for Special Surgery and a total of 70 participants are expected to be enrolled across all study sites. Participants will be asked to complete pain and function questionnaires at 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year after their injections. Additionally, participants will undergo follow-up MRIs at 6 months after their injections.